Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.89 ▼ -0.02
(-2.46%)
MKT CAP: $70.9M • VOL: 126.9K
52W L $1 52W H $3
ROARABLE / RQD
D- • 41/100
PIOTROSKI
1 / 9
CRDF // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $593.0K | $683.0K | $488.0K |
| YoY Revenue Growth % | -13.2% | +40.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$49.0M | -$48.7M | -$45.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$45.9K | -$45.4K | -$41.4K |
| EBITDA (Normalized) | -$48.9M | -$48.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$37.9M | -$37.7M | -$30.9M |
| Capital Expenditures (CapEx) | $44.0K | $80.0K | — |
| Free Cash Flow (FCF) | -$38.0M | -$37.8M | -$30.9M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $17.5M | $51.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $45.4M | $82.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CRDF.